FBIO — Fortress Biotech, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1429260 ·
Last close
$1.82
Market Cap
$60.70M
52W High
$4.53
52W Low
$1.64
ADV30
234,844
Next earnings
—
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 19,159,000 13,275,000 -7,193,000 -5,845,000 280,215,000 152,186,000 103,194,000
Jun 2026 18,718,000 12,575,000 -10,006,000 -468,000 316,715,000 196,576,000 110,629,000
Mar 2026 16,038,000 9,820,000 -7,739,000 110,373,000 356,874,000 255,841,000 154,500,000
Dec 2025 16,079,000 10,639,000 -4,789,000 -3,937,000 185,548,000 79,381,000 123,365,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$125,920,000
Investing CF
$2,791,000
Financing CF
$-6,521,000
CapEx
—
Dividends Paid
$-473,000
Buybacks
$-14,335,000
EPS Diluted TTM
$3.30
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-624,147,000
Inventory
$8,156,000
Receivables
$36,752,000
ST Investments
—
EBIT TTM
$152,999,000
Pretax Income TTM
$145,856,000
Interest Exp TTM
$7,143,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$68,466,000
EBITDA
$-24,979,000
Free Cash Flow
$-17,136,250
Enterprise Value
$-38,611,132
Total Cash
$196,576,000
Total Debt
$53,316,000
Shares Out
33,350,993
Trailing EPS
$2.76
Book Value
$4.93
ROE
116.0%
ROA
-7.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 63,262,000 -70,221,000 6,815,000 185,548,000 123,365,000 49,873,000 -65,777,000
Dec 2024 57,675,000 -111,240,000 -45,997,000 144,223,000 145,867,000 22,737,000 -80,191,000
Dec 2023 84,513,000 -139,199,000 -60,637,000 167,526,000 165,939,000 22,544,000 -128,225,000
Dec 2022 75,743,000 -203,564,000 -86,575,000 294,301,000 244,276,000 41,721,000 -179,401,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$68,466,000
NetIncome TTM
$111,818,000
OpCashFlow TTM
—
Assets (Latest)
$316,715,000
Forward EPS
$-1.76

Max Pain — expiry 2027-01-15

max pain strike: $2.50 · spot: $1.89 · call oi: 2,880 · put oi: 502
Expected Move to 2027-01-15: ±$0.65 (34.39%) — implied range $1.24 – $2.54 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
KZIA KAZIA THERAPEUTICS LTD $60.68M $5.31 —
LFVN Lifevantage Corp $60.62M $4.78 —
ACRV Acrivon Therapeutics, Inc. $61.28M $1.43 —
CRBP Corbus Pharmaceuticals Holdings, Inc. $62.03M $3.01 —
CTOR CITIUS ONCOLOGY, INC. $57.91M $0.55 —

News headlines (Yahoo Finance, 1h cache)

Fortress Biotech, Inc. Q3 2026 Earnings Call Summary
2026-11-14 02:30 · Yahoo
Fortress Biotech: 3 Key Takeaways for Long-Term Investors
2026-11-13 14:38 · Yahoo
Fortress Biotech (FBIO) Q3 2026 Earnings Call Transcript
2026-11-13 13:58 · Yahoo
Fortress Biotech: Q3 Earnings Snapshot
2026-11-13 13:11 · Yahoo
Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
2026-11-13 13:00 · Yahoo
Fortress Biotech Q3 Earnings Call Highlights
2026-11-13 01:14 · Yahoo
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
2026-11-10 21:05 · Yahoo
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript
2026-08-14 02:28 · Yahoo
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-13 20:05 · Yahoo
Fortress Biotech Q2 Earnings Call Highlights
2026-08-12 23:04 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.